Today, we're excited to report that researchers in the UK have identified a substance in the blood that shows
promise as a biomarker for HD.
«These plasma Ex-miRNAs show great
promise as biomarkers for MMVD disease monitoring and may also help us understand the pathophysiology of the disease, and subsequently devise more specific molecular therapies that can halt disease progression.»
Not exact matches
As promising new therapies such as those directly targeting survivor motor neuron (SMN) are entering clinical trials for infants, children, and adults with SMA, researchers are searching for biomarkers in blood that can monitor their effectivenes
As promising new therapies such
as those directly targeting survivor motor neuron (SMN) are entering clinical trials for infants, children, and adults with SMA, researchers are searching for biomarkers in blood that can monitor their effectivenes
as those directly targeting survivor motor neuron (SMN) are entering clinical trials for infants, children, and adults with SMA, researchers are searching for
biomarkers in blood that can monitor their effectiveness.
«These results show that SNTF has
promise as a blood
biomarker for sports - related concussion and beyond.
One
promising avenue of research involves searching for
biomarkers such
as tau proteins in the cerebrospinal fluid of patients.
«Macular degeneration: Drusen
as promising biomarkers for progression of the disease.»
«Future research will focus on optimizing the candidate therapies discovered by our team in this study
as well
as developing
biomarkers that can be used to test the efficacy of other potentially
promising drugs,» says Dr. Rothstein
Reliable
biomarkers such
as that identified by the researchers offer insight into how HIV - associated cognitive impairment develops but also
promises improved diagnostic testing and improved treatment decisions.
Using the large patient group in the ProTECT III trial, the researchers hope to validate
promising TBI
biomarkers as predictors of clinical outcome and also evaluate the relationship between progesterone treatment,
biomarker levels and outcome.
As MD Anderson moves toward molecular characterization of the cancers of all our patients, allowing their optimal assignments to
promising new targeted therapies and potential identification of
biomarkers of response and resistance, the department's mission includes thematic translational research and preclinical molecular pathology research.
Biomarkers associated with disease progression show
promise as detection tools in public health and biodefense and can guide drug and vaccine designers in their quest to disrupt the microbe's ability to infect.
The study of
biomarkers promises to bring us closer to a cure,
as scientists discover more about the root causes of the disease.